Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Tessalon
1. 104-31-4
2. Benzononatine
3. Tessalon
4. Benzononantin
5. Exangit
6. Ventussin
7. Benzonatatum
8. Tessalon-ciba
9. Ventussin-loz
10. Benzonatato
11. Tessalin
12. Zonatuss
13. Benzonatatum [inn-latin]
14. Benzonatato [inn-spanish]
15. Km65
16. 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl P-(butylamino)benzoate
17. P-(n)-butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester
18. 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate
19. Benzoic Acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl Ester
20. Chebi:3032
21. Nonaethyleneglycol Monomethyl Ether P-n-butylaminobenzoate
22. Tesalon
23. 4-(butylamino)benzoic Acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl Ester
24. Benzoic Acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl Ester
25. Nsc-760128
26. 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate
27. Benzoic Acid, P-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl Ester
28. Ncgc00016362-01
29. Cas-104-31-4
30. P-butylaminobenzoic Acid Omega-o-methylnonaethyleneglycol Ester
31. 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate
32. Dsstox_cid_2655
33. Dsstox_rid_76676
34. Dsstox_gsid_22655
35. 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl-4-butylaminobenzoate;3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl-4-butylaminobenzoate
36. Tessalon Perles (tn)
37. Benzonatate (usp/inn)
38. Einecs 203-194-7
39. Polyethyleneglycol-p-n-butylaminobenzoate Methyl Ester
40. Benzonatate [usp:inn:ban]
41. Hsdb 7933
42. P-(n)-butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [german]
43. Prestwick0_000012
44. Prestwick1_000012
45. Prestwick2_000012
46. Prestwick3_000012
47. Schembl28366
48. Bspbio_000043
49. 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate
50. Mls002154171
51. Spbio_001964
52. Bpbio1_000049
53. Gtpl7611
54. Chembl1374379
55. Dtxsid9022655
56. Hms1568c05
57. Hms2095c05
58. Hms2230m19
59. Hms3373i11
60. Hms3712c05
61. Km-65
62. Pharmakon1600-01503864
63. Hy-b1551
64. Zinc3830276
65. Tox21_110398
66. Nsc760128
67. 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl 4-(butylamino)benzoate
68. Akos015891366
69. Tox21_110398_1
70. Ccg-213706
71. Db00868
72. Nsc 760128
73. Ncgc00016362-02
74. Ncgc00016362-03
75. Ncgc00016362-05
76. Smr001233469
77. Ab00513795
78. Cs-0013413
79. Ft-0622718
80. D00242
81. Ab00513795_06
82. Sr-01000841197
83. J-001145
84. Q2070778
85. Sr-01000841197-2
86. Nonaethyleneglycol-p-n-butylaminobenzoate Methyl Ester
87. 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl 4-(butylamino)benzoate #
Molecular Weight | 603.7 g/mol |
---|---|
Molecular Formula | C30H53NO11 |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 33 |
Exact Mass | 603.36186151 g/mol |
Monoisotopic Mass | 603.36186151 g/mol |
Topological Polar Surface Area | 121 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 565 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Benzonatate |
PubMed Health | Benzonatate (By mouth) |
Drug Classes | Antitussive |
Drug Label | Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.Each soft gelatin capsule, for oral administration, contains 100 mg or 200 mg of b... |
Active Ingredient | Benzonatate |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 100mg; 150mg |
Market Status | Prescription |
Company | Thepharmanetwork; Orit Labs; Sun Pharm Inds; Zydus Pharms Usa; The Pharma Network; Banner Pharmacaps; Mikart |
2 of 4 | |
---|---|
Drug Name | Tessalon |
PubMed Health | Benzonatate (By mouth) |
Drug Classes | Antitussive |
Drug Label | TESSALON, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.Each TESSALON Perle contains:Benzonatate, USP 100 mgTESSALON Perles (capsules) also c... |
Active Ingredient | Benzonatate |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 100mg |
Market Status | Prescription |
Company | Pfizer |
3 of 4 | |
---|---|
Drug Name | Benzonatate |
PubMed Health | Benzonatate (By mouth) |
Drug Classes | Antitussive |
Drug Label | Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.Each soft gelatin capsule, for oral administration, contains 100 mg or 200 mg of b... |
Active Ingredient | Benzonatate |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 100mg; 150mg |
Market Status | Prescription |
Company | Thepharmanetwork; Orit Labs; Sun Pharm Inds; Zydus Pharms Usa; The Pharma Network; Banner Pharmacaps; Mikart |
4 of 4 | |
---|---|
Drug Name | Tessalon |
PubMed Health | Benzonatate (By mouth) |
Drug Classes | Antitussive |
Drug Label | TESSALON, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.Each TESSALON Perle contains:Benzonatate, USP 100 mgTESSALON Perles (capsules) also c... |
Active Ingredient | Benzonatate |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 100mg |
Market Status | Prescription |
Company | Pfizer |
Antitussive Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 2011)
Tessalon is indicated for the symptomatic relief of cough. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for TESSALON (benzonatate) capsule (February 2011). Available from, as of July 7, 2011: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=benzonatate
Accidental ingestion of Tessalon resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately
US Natl Inst Health; DailyMed. Current Medication Information for TESSALON (benzonatate) capsule (February 2011). Available from, as of July 7, 2011: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=benzonatate
Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.
US Natl Inst Health; DailyMed. Current Medication Information for TESSALON (benzonatate) capsule (February 2011). Available from, as of July 7, 2011: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=benzonatate
Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.
US Natl Inst Health; DailyMed. Current Medication Information for TESSALON (benzonatate) capsule (February 2011). Available from, as of July 7, 2011: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=benzonatate
Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.
US Natl Inst Health; DailyMed. Current Medication Information for TESSALON (benzonatate) capsule (February 2011). Available from, as of July 7, 2011: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=benzonatate
For more Drug Warnings (Complete) data for Benzonatate (8 total), please visit the HSDB record page.
Benzonatate is indicated for the symptomatic relief of cough.
Benzonatate suppresses cough associated with both acute and chronic respiratory conditions. Its works by desensitizing the pulmonary stretch receptors involved in the cough reflex. There are limited clinical trials of benzonatate; however, earlier studies demonstrated inhibition of experimentally-induced cough and subjectively-measured pathological cough by benzonatate. Benzonatate has no inhibitory effects on the respiratory center in recommended dosage. Its onset of action is within 15 to 20 minutes following administration and its duration of effect is about 3 to 8 hours.
Antitussive Agents
Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)
R - Respiratory system
R05 - Cough and cold preparations
R05D - Cough suppressants, excl. combinations with expectorants
R05DB - Other cough suppressants
R05DB01 - Benzonatate
Absorption
Following oral administration, benzonatate enters the systemic circulation via gastrointestinal absorption. The Cmax of benzonatate following oral administration of 100 mg in healthy Chinese volunteers was 1063 460 ng/mL.
Route of Elimination
There is limited information on the route of elimination of benzonatate.
Volume of Distribution
There is limited information on the volume of distribution of benzonatate.
Clearance
There is limited information on the clearance of benzonatate.
Benzonatate is hydrolyzed to the major metabolite 4-(butylamino)benzoic acid (BABA) by plasma butyrylcholinesterase (BChE).
The half life of benzonatate following oral administration of 100 mg in healthy Chinese volunteers was 1.01 0.41 h.
Benzonatate is a local anesthetic drug that acts peripherally by anesthetizing and reducing the activity of vagal stretch receptors or nerve fibres located in the respiratory passages, lungs, and pleura. Once the stretch receptors are stimulated, they send impulses to the cough centre located in the medulla via an afferent pathway consisting of sensory nerve fibres or the vagus nerve. The efferent signal is then generated that sends impulses to the expiratory muscles to produce a cough. Anesthetizing these receptors by benzonatate results in the inhibition of the cough reflex activity and cough production. Benzonatate also inhibits the transmission of impulses of the cough reflex in the vagal nuclei of the medulla. There are several proposed mechanisms of benzonatate; it is also a potent voltage-gated sodium channel inhibitor.
Benzonatate apparently inhibits cough production by anesthetizing stretch receptors of vagal afferent fibers in the bronchi, alveoli, and pleura that mediate the cough reflex; the drug also suppresses transmission of the cough reflex at the level of the medulla where the afferent impulse is transmitted to the motor nerves. The relationship between local anesthetic action and peripheral action on sensory nerve endings is not clear.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39002
Submission : 2023-12-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12327
Submission : 1997-01-21
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-04-03
Pay. Date : 2013-05-03
DMF Number : 21703
Submission : 2008-06-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-06-06
Pay. Date : 2013-05-23
DMF Number : 5196
Submission : 1983-12-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24194
Submission : 2010-09-20
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12421
Submission : 1997-03-14
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-31
Pay. Date : 2014-10-23
DMF Number : 7843
Submission : 1988-12-19
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
18 May 2021
Reply
27 Apr 2021
Reply
24 Mar 2016
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Benzonatate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Benzonatate, including repackagers and relabelers. The FDA regulates Benzonatate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Benzonatate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Benzonatate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Benzonatate supplier is an individual or a company that provides Benzonatate active pharmaceutical ingredient (API) or Benzonatate finished formulations upon request. The Benzonatate suppliers may include Benzonatate API manufacturers, exporters, distributors and traders.
click here to find a list of Benzonatate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Benzonatate DMF (Drug Master File) is a document detailing the whole manufacturing process of Benzonatate active pharmaceutical ingredient (API) in detail. Different forms of Benzonatate DMFs exist exist since differing nations have different regulations, such as Benzonatate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Benzonatate DMF submitted to regulatory agencies in the US is known as a USDMF. Benzonatate USDMF includes data on Benzonatate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Benzonatate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Benzonatate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Benzonatate Drug Master File in Korea (Benzonatate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Benzonatate. The MFDS reviews the Benzonatate KDMF as part of the drug registration process and uses the information provided in the Benzonatate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Benzonatate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Benzonatate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Benzonatate suppliers with KDMF on PharmaCompass.
A Benzonatate written confirmation (Benzonatate WC) is an official document issued by a regulatory agency to a Benzonatate manufacturer, verifying that the manufacturing facility of a Benzonatate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Benzonatate APIs or Benzonatate finished pharmaceutical products to another nation, regulatory agencies frequently require a Benzonatate WC (written confirmation) as part of the regulatory process.
click here to find a list of Benzonatate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Benzonatate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Benzonatate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Benzonatate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Benzonatate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Benzonatate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Benzonatate suppliers with NDC on PharmaCompass.
Benzonatate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Benzonatate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Benzonatate GMP manufacturer or Benzonatate GMP API supplier for your needs.
A Benzonatate CoA (Certificate of Analysis) is a formal document that attests to Benzonatate's compliance with Benzonatate specifications and serves as a tool for batch-level quality control.
Benzonatate CoA mostly includes findings from lab analyses of a specific batch. For each Benzonatate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Benzonatate may be tested according to a variety of international standards, such as European Pharmacopoeia (Benzonatate EP), Benzonatate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Benzonatate USP).
LOOKING FOR A SUPPLIER?